3-(3-{3-[3-benzyl-8-(trifluoromethyl)quinolin-4-yl]phenoxy}propyl)-5-(4-isopropoxyphenyl)-5-methylimidazolidine-2,4-dione | 1192758-01-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 3-(3-{3-[3-benzyl-8-(trifluoromethyl)quinolin-4-yl]phenoxy}propyl)-5-(4-isopropoxyphenyl)-5-methylimidazolidine-2,4-dione
• 英文别名: 3-[3-[3-[3-Benzyl-8-(trifluoromethyl)quinolin-4-yl]phenoxy]propyl]-5-methyl-5-(4-propan-2-yloxyphenyl)imidazolidine-2,4-dione
• CAS: 1192758-01-2
• 化学式: C₃₉H₃₆F₃N₃O₄
• 分子量: 667.728
• InChiKey: NCURMJAONWQGCQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.5
• 重原子数：
  49
• 可旋转键数：
  11
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  80.8
• 氢给体数：
  1
• 氢受体数：
  8

文献信息

• QUINOLINE COMPOUNDS
  申请人：KOURA Minoru

  公开号：US20100016327A1

  公开（公告）日：2010-01-21

  [Object] To provide a novel LXRβ agonist that is useful as a preventative and/or therapeutic agent for atherosclerosis; arteriosclerosis such as those resulting from diabetes; dyslipidemia; hypercholesterolemia; lipid-related diseases; inflammatory diseases that are caused by inflammatory cytokines; skin diseases such as allergic skin diseases; diabetes; or Alzheimer's disease. [Solving Means] A quinoline compound represented by the following general formula (1) or salt thereof, or their solvate.

  提供一种新型的LXRβ激动剂，可用作预防和/或治疗动脉粥样硬化；动脉硬化，如糖尿病引起的动脉硬化；血脂异常；高胆固醇血症；与脂质相关的疾病；由炎症性细胞因子引起的炎症性疾病；过敏性皮肤病；糖尿病；或阿尔茨海默病的治疗剂。通过以下一般式（1）表示的喹啉化合物或其盐，或它们的溶剂化合物。
• METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS
  申请人：The Rockefeller University

  公开号：EP3402477A2

  公开（公告）日：2018-11-21
• TREATMENT AND DIAGNOSIS OF CANCER
  申请人：Rgenix, Inc.

  公开号：US20190125745A1

  公开（公告）日：2019-05-02

  This invention features compounds that modulate the activity of liver X receptors, pharmaceutical compositions including the compounds of the invention, and methods of utilizing those compositions for modulating the activity of liver X receptors for the treatment of cancer.
• US8008306B2
  申请人：——

  公开号：US8008306B2

  公开（公告）日：2011-08-30
• [EN] TREATMENT AND DIAGNOSIS OF CANCER<br/>[FR] TRAITEMENT ET DIAGNOSTIC DU CANCER
  申请人：RGENIX INC

  公开号：WO2016100619A2

  公开（公告）日：2016-06-23

  This invention features compounds that modulate the activity of liver X receptors, pharmaceutical compositions including the compounds of the invention, and methods of utilizing those compositions for modulating the activity of liver X receptors for the treatment of cancer.